Literature DB >> 707294

Isoproterenol as a potential pulmonary vasodilator in primary pulmonary hypertension.

F S Daoud, J T Reeves, D B Kelly.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 707294     DOI: 10.1016/0002-9149(78)90102-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  15 in total

Review 1.  Pulmonary hypertension in children: perioperative management.

Authors:  F A Burrows; J R Klinck; M Rabinovitch; D J Bohn
Journal:  Can Anaesth Soc J       Date:  1986-09

2.  Management of primary pulmonary hypertension.

Authors:  C M Oakley
Journal:  Br Heart J       Date:  1985-01

Review 3.  Primary pulmonary hypertension.

Authors:  S G Haworth
Journal:  Br Heart J       Date:  1983-06

4.  Pulmonary vasodilator responses to nitroprusside and nitroglycerin in the dog.

Authors:  P J Kadowitz; P Nandiwada; C A Gruetter; L J Ignarro; A L Hyman
Journal:  J Clin Invest       Date:  1981-03       Impact factor: 14.808

5.  Sublingual isoprenaline in treatment of primary pulmonary hypertension: discussion paper.

Authors:  J F Ackroyd
Journal:  J R Soc Med       Date:  1985-06       Impact factor: 5.344

6.  Vasodilator therapy of pulmonary hypertension in the CRST syndrome.

Authors:  J McWeeney; P Finnegan
Journal:  Ir J Med Sci       Date:  1982-05       Impact factor: 1.568

7.  Primary pulmonary hypertension: modern approaches to an old problem.

Authors:  S Fein; W Frishman
Journal:  Lung       Date:  1980       Impact factor: 2.584

8.  Comparison of primary plexogenic arteriopathy in adults and children. A morphometric study in 40 patients.

Authors:  S Yamaki; C A Wagenvoort
Journal:  Br Heart J       Date:  1985-10

Review 9.  Drug treatment of primary pulmonary hypertension.

Authors:  A A McLeod; D E Jewitt
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

10.  Influence of prostaglandin synthesis inhibitors on pulmonary vasodilatory effects of hydralazine in dogs with hypoxic pulmonary vasoconstriction.

Authors:  L J Rubin; J D Lazar
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.